OBJECTIVES: Patient reported outcomes (PROs) are important treatment endpoints in inflammatory bowel diseases (IBD). We evaluated the gastrointestinal (GI) PRO Measurement Information System (PROMIS) in IBD subjects. METHODS: Crohn's and Colitis Foundation of America's Partners is an Internet-based cohort of IBD subjects. Participants complete surveys, including demographics, disease characteristics, PROMIS domains, disease activity (short Crohn's disease activity index or simple clinical colitis activity index) and quality of life (QoL) indices. In a nested cross-sectional study, we used univariate and bivariate analyses to assess associations between 8 GI-PROMIS domains (reflux, swallowing, diarrhea, nausea, belly pain, gas, incontinence, and constipation) and QoL and disease activity indices. RESULTS: The study included 2,378 Crohn's Disease (CD) and 1,455 ulcerative colitis (UC) respondents with a median age of 41 years. Median disease duration was 11 years for CD subjects and 8 years for UC subjects; 57% of CD subjects and 42% of UC subjects were in remission. Among symptomatic CD subjects, those with active CD reported significantly worse symptoms on all 8 domains than those in remission. The same was observed for UC subjects with the exception of disrupted swallowing. IBD subjects with worse QoL reported significantly worse symptoms on all 8 domains compared to those with better QoL. CONCLUSIONS: In IBD subjects experiencing GI symptoms, GI-PROMIS domains were strongly associated with disease activity and QoL indices. GI-PROMIS holds potential as PRO measures in IBD and correlates with other validated indices in this population.
OBJECTIVES:Patient reported outcomes (PROs) are important treatment endpoints in inflammatory bowel diseases (IBD). We evaluated the gastrointestinal (GI) PRO Measurement Information System (PROMIS) in IBD subjects. METHODS: Crohn's and Colitis Foundation of America's Partners is an Internet-based cohort of IBD subjects. Participants complete surveys, including demographics, disease characteristics, PROMIS domains, disease activity (short Crohn's disease activity index or simple clinical colitis activity index) and quality of life (QoL) indices. In a nested cross-sectional study, we used univariate and bivariate analyses to assess associations between 8 GI-PROMIS domains (reflux, swallowing, diarrhea, nausea, belly pain, gas, incontinence, and constipation) and QoL and disease activity indices. RESULTS: The study included 2,378 Crohn's Disease (CD) and 1,455 ulcerative colitis (UC) respondents with a median age of 41 years. Median disease duration was 11 years for CD subjects and 8 years for UC subjects; 57% of CD subjects and 42% of UC subjects were in remission. Among symptomatic CD subjects, those with active CD reported significantly worse symptoms on all 8 domains than those in remission. The same was observed for UC subjects with the exception of disrupted swallowing. IBD subjects with worse QoL reported significantly worse symptoms on all 8 domains compared to those with better QoL. CONCLUSIONS: In IBD subjects experiencing GI symptoms, GI-PROMIS domains were strongly associated with disease activity and QoL indices. GI-PROMIS holds potential as PRO measures in IBD and correlates with other validated indices in this population.
Authors: Haihao Sun; Jessica J Lee; Elektra J Papadopoulos; Catherine S Lee; Robert M Nelson; Hari C Sachs; William J Rodriguez; Andrew E Mulberg Journal: J Pediatr Gastroenterol Nutr Date: 2014-01 Impact factor: 2.839
Authors: Christopher V Almario; William D Chey; Dinesh Khanna; Sasan Mosadeghi; Shahzad Ahmed; Elham Afghani; Cynthia Whitman; Garth Fuller; Mark Reid; Roger Bolus; Buddy Dennis; Rey Encarnacion; Bibiana Martinez; Jennifer Soares; Rushaba Modi; Nikhil Agarwal; Aaron Lee; Scott Kubomoto; Gobind Sharma; Sally Bolus; Brennan M R Spiegel Journal: Am J Gastroenterol Date: 2016-08-02 Impact factor: 10.864
Authors: Magnus Simrén; Jenny Axelsson; Rolf Gillberg; Hasse Abrahamsson; Jan Svedlund; Einar S Björnsson Journal: Am J Gastroenterol Date: 2002-02 Impact factor: 10.864
Authors: Johanna Haapamäki; Ulla Turunen; Risto P Roine; Martti A Färkkilä; Perttu E T Arkkila Journal: Qual Life Res Date: 2009-07-23 Impact factor: 4.147
Authors: Brennan M R Spiegel; Ron D Hays; Roger Bolus; Gil Y Melmed; Lin Chang; Cynthia Whitman; Puja P Khanna; Sylvia H Paz; Tonya Hays; Steve Reise; Dinesh Khanna Journal: Am J Gastroenterol Date: 2014-09-09 Impact factor: 10.864
Authors: Edward L Barnes; Michael D Kappelman; Millie D Long; Donna M Evon; Christopher F Martin; Robert S Sandler Journal: Am J Gastroenterol Date: 2019-04 Impact factor: 10.864
Authors: Christopher V Almario; Megana L Ballal; William D Chey; Carl Nordstrom; Dinesh Khanna; Brennan M R Spiegel Journal: Am J Gastroenterol Date: 2018-10-15 Impact factor: 10.864
Authors: Kendra Kamp; Sharon Dudley-Brown; Margaret Heitkemper; Gwen Wyatt; Barbara Given Journal: Res Nurs Health Date: 2019-10-10 Impact factor: 2.228
Authors: Adil E Bharucha; Charles H Knowles; Isabelle Mack; Allison Malcolm; Nicholas Oblizajek; Satish Rao; S Mark Scott; Andrea Shin; Paul Enck Journal: Nat Rev Dis Primers Date: 2022-08-10 Impact factor: 65.038
Authors: Julie M Deleemans; Faye Chleilat; Raylene A Reimer; Mohamad Baydoun; Katherine-Ann Piedalue; Dana E Lowry; Jan-Willem Henning; Linda E Carlson Journal: Curr Oncol Date: 2022-04-21 Impact factor: 3.109
Authors: Sun Jung Oh; Garth Fuller; Devin Patel; Carine Khalil; William Spalding; Arpita Nag; Brennan M R Spiegel; Christopher V Almario Journal: Am J Gastroenterol Date: 2020-06 Impact factor: 12.045